Prostate Cancer Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

September 16 13:35 2021
Prostate Cancer Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working
DelveInsight Business Research LLP
DelveInsight’s “Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Prostate Cancer Market Report:

  1. The total prevalent cases of Prostate Cancer in the 7MM were observed to be  6,985,331 cases in 2018, and are expected to increase during the study period (2018–2030). 

  2. The highest number of prevalent cases was observed in the United States with  3,266,625 cases in 2018 which will increase during the study period (2018–2030). 

  3. On the other hand, in EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 393,977 cases in 2020, followed by France and Italy. 

Key benefits of the report:

  1. Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Prostate Cancer Epidemiology and Prostate Cancer  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Prostate Cancer market report provides insights on the current and emerging therapies.

  3. Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prostate Cancer market.

Got queries? Click here to know more about the Prostate Cancer Market Landscape.

Prostate Cancer Overview

Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide. In the majority of the cases, the symptoms of prostate cancer are not apparent in the early stages of the disease. Due to the proximity of the prostate gland to the bladder and urethra, prostate cancer may be accompanied by a variety of urinary symptoms, especially in the early stages. Depending on its size and location, a tumor may press on and constrict the urethra, inhibiting the flow of urine. Furthermore, Prostate cancer may metastasize and form tumors in nearby organs or bones. If cancer spreads to the spine, it may press on the spinal nerves. Symptoms of Prostate Cancer often differ from patient to patient. 

Prostate Cancer Market 

The dynamics of the Prostate Cancer market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as AstraZeneca/Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, and Merck Sharp & Dohme, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ Prostate Cancer Market Landscape 

Prostate Cancer Pipeline Therapies and Key Companies 

  1. Lynparza: AstraZeneca/Merck Sharp & Dohme 

  2. Opdivo: Bristol-Myers Squibb  

  3. Lutathera: Novartis  

  4. Relugolix: Myovant Sciences

  5. Niraparib: Janssen Research & Development 

  6. HC-1119: Hinova Pharmaceuticals USA

  7. Ipatasertib: Hoffmann-La Roche

  8. Talazoparib: Pfizer/Astellas Pharma 

  9. Rucaparib :Clovis Oncology 

  10. ProstAtak :Advantagene or Candel Therapeutics 

  11. Keytruda :Merck Sharp & Dohme, and others

Prostate Cancer Market Drivers 

  • Increasing Use of Biomarker Testing 

  • Rising Geriatric Population and High Prevalence  Rate of Prostate Cancer 

  • The surge in Awareness Regarding the Treatment of Prostate Cancer

  • Increase in Demand for  Prostate Cancer Treatment Products

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Prostate Cancer Patient Share (%) Overview at a Glance

5. Prostate Cancer Market Overview at a Glance

6. Prostate Cancer Disease Background and Overview

7. Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Prostate Cancer 

9. Prostate Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. Prostate Cancer Emerging Therapies

12. Prostate Cancer Market Outlook

13. Country-Wise Prostate Cancer Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Prostate Cancer Market Outlook 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/